Evidence map›Paper›PMID 35793834›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2022

Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane.

Irina Teslenko, Julia Trudeau, Shaman Luo, Christy J W Watson, Gang Chen, Cristina I Truica, Philip Lazarus

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Impact of combined UGT2B17 and GSTA1 genotypes on exemestane pharmacogenetics.Drug metabolism and disposition: the biological fate of chemicals · 2025
    Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Irina TeslenkoDepartment of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington (I.T., J.T., S.L., C.J.W.W., G.C., P.L.) and Penn State University, College of Medicine, Division of Hematology and Oncology, Department of Medicine, Hershey, Pennsylvania (C.I.T.).ORCID 0000-0002-9323-0264
Julia TrudeauDepartment of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington (I.T., J.T., S.L., C.J.W.W., G.C., P.L.) and Penn State University, College of Medicine, Division of Hematology and Oncology, Department of Medicine, Hershey, Pennsylvania (C.I.T.).
Shaman LuoDepartment of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington (I.T., J.T., S.L., C.J.W.W., G.C., P.L.) and Penn State University, College of Medicine, Division of Hematology and Oncology, Department of Medicine, Hershey, Pennsylvania (C.I.T.).ORCID 0000-0002-2435-5610
Christy J W WatsonDepartment of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington (I.T., J.T., S.L., C.J.W.W., G.C., P.L.) and Penn State University, College of Medicine, Division of Hematology and Oncology, Department of Medicine, Hershey, Pennsylvania (C.I.T.).ORCID 0000-0003-1049-1387
Gang ChenDepartment of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington (I.T., J.T., S.L., C.J.W.W., G.C., P.L.) and Penn State University, College of Medicine, Division of Hematology and Oncology, Department of Medicine, Hershey, Pennsylvania (C.I.T.).ORCID 0000-0002-4353-3806
Cristina I TruicaDepartment of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington (I.T., J.T., S.L., C.J.W.W., G.C., P.L.) and Penn State University, College of Medicine, Division of Hematology and Oncology, Department of Medicine, Hershey, Pennsylvania (C.I.T.).
Philip LazarusDepartment of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington (I.T., J.T., S.L., C.J.W.W., G.C., P.L.) and Penn State University, College of Medicine, Division of Hematology and Oncology, Department of Medicine, Hershey, Pennsylvania (C.I.T.) phil.lazarus@wsu.edu.ORCID 0000-0002-8686-0874
Pennsylvania State University · US

Funding

Role of pharmacogenetics on exemestane metabolism and toxicityR01CA164366 · NCI · WASHINGTON STATE UNIVERSITY · PI LAZARUS, PHILIP · 2012 to 2016
$2.4M
NCI NIH HHS R01 CA164366
6 · The paper itself

Abstract

Exemestane (EXE) is used to treat postmenopausal women diagnosed with estrogen receptor positive (ER+) breast cancer. A major mode of metabolism of EXE and its active metabolite, 17

Indexed as

Aromatase InhibitorsBreast NeoplasmsAllelesAndrostadienesCytosolFemaleGlutathioneGlutathione TransferaseHumansLiverAndrostadienesAromatase InhibitorsexemestaneGlutathioneGlutathione Transferase

Identifiers

PMID35793834
PMCPMC9426760
OpenAlexW4284889417

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.